Grant of incentives on export of Senna leaves, Pods and Vinca Rose Routs

1023. SHRI RAJNI RANJAN SAHU:

CHOWDHARY RAM SEWAK:

Will the Minister of COMMERCE be pleased to refer to the answer to Unstarred Question 2044 given in the Rajya Sabha on the 29th March, 1990 and state:

(a) whether it is a fact that incentives given on export of Senna leaves, Pods and Vinca Rose Roots are the same as in the case of end products;

(b) whether it is also a fact that CCS, REP Licence facility etc. are allowed on the export of basic material;

(c) whether it is also a fact that his Ministry are considering to withdraw the facilities allowed on basic materal and increase incentive on and products to boost exports and earn more foreign exchange; and

(d) if so, what are the details thereof and by when such a proposal would be implemented?

THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE (SHRI ARANGIL SREEDHARAN): (a) and (b) At present export of Senna leaves, Pods and Vinca Rose Roots is entitled to REP @ 10% and no Cash Compensatory Support (CCS). The drugs manufactured out of them are entitled to CCS @ 15% and REP @ 15%. In the case of finished formulations in dosage form, REP at 20% is admissible.

(c) No such proposal is under consideration.

(d) Does not arise.

Issue of advance licence for raw materials

1024. SHRI RAJNI RANJAN SAHU:
CHOWDHARY RAM SEWAK:

Will the Minister of COMMERCE be pleased to refer to the Starded Question 260 given in the Rajya Sabha on the 29th March, 1990 and state;

(a) whether it is a fact that while getting advance licenees for raw materials required for the export of Pyrazinamide, Cephalexin, Erythomycin, Ethambutol and Ampicillin all the raw materials were not shown to show 33 per cent higher realisation than the CIF content;

(b) whether it is also a fact that additional raw materials against the above drugs were imported under OGL by the exporters;

(c) if so, what was the raw material imported by each exported under OGL for utilisation against export during the last three years, year-wise;

(d) whether it is a fact that instead of value additon, there was value less in exports of these drugs and several